Results 183 subjects enrolled, 124 with INI-resistance at screening and 59 with historical (but no screening) resistance. Population was advanced: at BL, median CD4 140, prior ART 13 yrs, 56% CDC Class C; 79% had !2 NRTI, 75% !1 NNRTI, and 70% !2 PI resistance-associated mutations, and 61% had non-R5 HIV detected. Of the 114 subjects who had the opportunity to complete 24 weeks on study before data cutoff, 72 (63%) had B50 c/mL RNA at Week 24 (SNAPSHOT algorithm). Mean HIV RNA declined by 1.4 log 10 c/mL (95% CI: 1.3, 1.5; p B 0.001) at Day 8; response differed by genotype pathway (Table) .
# Key secondary mutations comprised G140_ACS, L741, E138_AKT.
In subjects with Q148 pathway mutations, virologic response decreased with increasing number of secondary mutations. Background overall susceptibility score (OSS) was not associated with Wk 24 response: % B50 c/mL were 83%, 63%, 59% and 69% for OSS 0, 1, 2 and !2, respectively. Discontinuations due to adverse events were uncommon (6/183, 3%); the most common drug-related AEs were diarrhoea, nausea and headache, each reported in only 5% of subjects. 
